Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Corrado Ficorella, Paola Bordi et al.|European Journal of Cancer|2020Cited by 71
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancerAlessandra Gennari, Stefano Iacobelli, Michele De Tursi et al.|Breast Cancer Research and Treatment|2008Cited by 12
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|medRxiv|2020Cited by 6
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)Michele De Tursi, Silvia Iacobelli, Consiglia Carella et al.|Journal of Clinical Oncology|2007Cited by 2